Today: 29 April 2026
Browse Category

TSX:TLRY 23 November 2025 - 14 December 2025

Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Tilray Brands shares surged 44% to $12.15 Friday after reports that President Trump may direct agencies to reclassify marijuana as a Schedule III drug. Volume reached 84.2 million shares, with prices swinging between $10.32 and $13.85. The move follows Tilray’s 1-for-10 reverse stock split effective Dec. 2. Timing of any federal action remains uncertain.
14 December 2025
···
Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)

Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)

Tilray Brands shares surged 28% in premarket trading on December 12, 2025, after reports that President Trump may push to reclassify marijuana as a Schedule III substance. The move sparked a rally across cannabis stocks. The Washington Post said no final decision had been made, according to a White House official.
12 December 2025
···
Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook

Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook

Tilray Brands shares surged 12.4% to $8.09 on December 9, 2025, after weeks of steep declines and heavy trading volume. The rebound followed news of a Florida bill to allow home cannabis cultivation and renewed speculation over U.S. federal rescheduling. Tilray remains down 65% from its October high and recently completed a 1-for-10 reverse stock split.
10 December 2025
···
Tilray Stock Today, November 23, 2025: TLRY Under $1 as AI Trading Signals, Hemp Rules and Big Holders Collide

Tilray Stock Today, November 23, 2025: TLRY Under $1 as AI Trading Signals, Hemp Rules and Big Holders Collide

Tilray Brands shares closed at $0.9059 on Friday, falling below $1 after a 12% weekly drop. Trading volume hit about 29.4 million shares, with a market cap near $1 billion. New AI-driven trading plans and regulatory uncertainty are drawing attention. The stock remains up over 90% from late-spring lows, fueled by U.S. cannabis policy speculation.
23 November 2025
····
Tilray Brands (TLRY) on November 23, 2025: Stock Under $1, Fresh AI Trading Signals, and a Tug-of-War Between Fundamentals and Regulation

Tilray Brands (TLRY) on November 23, 2025: Stock Under $1, Fresh AI Trading Signals, and a Tug-of-War Between Fundamentals and Regulation

Tilray Brands’ U.S. shares closed at $0.91 Friday, down 12% for the week and 56% below their 52-week high. Stock Traders Daily’s new AI-driven analysis rates TLRY “Weak” across all time frames, with key technical levels flagged between $1.12 and $1.47. Valueinvesting.io’s updated model assigns a fair value of –$7.67 per share, calling the stock “deeply overvalued.”
23 November 2025
··

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 3:00 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop